(Alliance News) - GSK PLC on Wednesday noted five-year data for ViiV Healthcare's HIV treatment Cabenuva, which the lead study author found "highly encouraging". Read More
(Alliance News) - GSK PLC on Wednesday announced US regulatory approval for its chronic hepatitis B treatment Hibsago, while Hutchmed China Ltd confirmed the completion of a separate licensing agreement with GSK worth up to USD1.30 billion. Read More
(Alliance News) - Fresnillo says it has maintained its annual production forecast, GSK has landed a US drug approval and Quilter reports its net inflows for the year have already topped 2025's level. Meanwhile, drilling at a North Sea gas field co-owned by Shell has been approved. Read More
(Alliance News) - GSK PLC on Monday announced an approval for Jemperli in the US for a form of locally advanced rectal cancer. Read More
(Alliance News) - GSK PLC on Monday set out its first batch of global data for the risvutatug rezetecan drug. Read More
(Alliance News) - LondonMetric reports growth in rental income over its first half, GSK posts promising results from a drug trial while Volex expects annual profit at the upper end of market forecasts. Meanwhile, Abenojar Tungsten, set to list later this month, could be worth more than GBP600 million. Read More
(Alliance News) - The FTSE 100 ended higher on Wednesday, despite strong US inflation data, as the Bank of England's chief economist played down fears of multiple interest rate rises in the UK. Read More
(Alliance News) - The FTSE 100 ended higher on Wednesday, despite strong US inflation data, as the Bank of England's chief economist played down fears of multiple interest rate rises in the UK. Read More
(Alliance News) - The FTSE 100 outperformed European peers on Thursday as higher oil prices continued to weigh on blue chips. Read More
(Alliance News) - GSK PLC on Tuesday said HIV treatment Cabenuva has met its primary endpoint in a phase 3 trial. Read More
(Alliance News) - Stock prices in London were higher at midday on Tuesday, as pharmaceutical stocks advanced and investors digested UK mortgage data showing approvals at their lowest level since the end of 2023. Read More
(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More
(Alliance News) - Stock prices in London opened higher on Tuesday, as pharmaceutical and mining stocks advanced, while oil prices eased amid signs of progress towards renewed talks between the US and Iran. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Initiates the phase Ia portion, or initial dose-finding stage, of a global clinical trial of HMPL-A830 in patients with advanced or metastatic solid tumours. Says the first patient received an initial dose in China on September 24. The phase I study will assess safety, tolerability, pharmacokinetics, immunogenicity and preliminary efficacy, with the initial dose-escalation stage intended to determine the maximum tolerated dose and recommended dose for expansion. Hutchmed says the antibody-targeted therapy combines a KRAS inhibitor with an anti-EGFR antibody to target KRAS-altered, EGFR-expressing tumours. The company is responsible for global phase I development under an agreement with GSK, which holds worldwide rights outside mainland China, Hong Kong, Macau and Taiwan. Read More
(Alliance News) - Land Securities agrees to sell a London office for GBP211 million, while Entain maintains its annual guidance despite an online betting ban in Brazil. HICL Infrastructure invests around GBP68 million in Scandinavian rail freight operator Hector Rail. Read More
(Alliance News) - Stocks in London made modest progress on Friday as lower oil prices amid hopes of progress in US-Iran negotiations helped offset concerns over another rise in bond yields. Read More
Hikma Pharmaceuticals PLC - London-based pharmaceutical maker - Appoints Rebecca Hall as chief financial officer, effective from a to-be-announced date in the first quarter of 2027, which Hikma will confirm "in due course." Hall joins Hikma from ViiV Healthcare Ltd, a specialist HIV pharmaceutical company majority owned by GSK PLC, with pharma firm Shionogi & Co Ltd as a shareholder. At ViiV Healthcare, Hall is senior vice president and CFO, responsible for finance, supply chain and business development. Hikma Chair Victoria Hull said: "Becky's appointment is a further step in broadening the expertise we have across both the executive team and the board, positioning us well for long-term sustainable growth." Read More
(Alliance News) - Vault Ventures PLC on Monday announced a change of name and leadership as it moves towards bringing its first product to the market. Read More